These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 28274144)

  • 1. Prospect of rindopepimut in the treatment of glioblastoma.
    Elsamadicy AA; Chongsathidkiet P; Desai R; Woroniecka K; Farber SH; Fecci PE; Sampson JH
    Expert Opin Biol Ther; 2017 Apr; 17(4):507-513. PubMed ID: 28274144
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase II, multicenter trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma: the ACT III study.
    Schuster J; Lai RK; Recht LD; Reardon DA; Paleologos NA; Groves MD; Mrugala MM; Jensen R; Baehring JM; Sloan A; Archer GE; Bigner DD; Cruickshank S; Green JA; Keler T; Davis TA; Heimberger AB; Sampson JH
    Neuro Oncol; 2015 Jun; 17(6):854-61. PubMed ID: 25586468
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rindopepimut, a 14-mer injectable peptide vaccine against EGFRvIII for the potential treatment of glioblastoma multiforme.
    Del Vecchio CA; Wong AJ
    Curr Opin Mol Ther; 2010 Dec; 12(6):741-54. PubMed ID: 21154166
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial.
    Weller M; Butowski N; Tran DD; Recht LD; Lim M; Hirte H; Ashby L; Mechtler L; Goldlust SA; Iwamoto F; Drappatz J; O'Rourke DM; Wong M; Hamilton MG; Finocchiaro G; Perry J; Wick W; Green J; He Y; Turner CD; Yellin MJ; Keler T; Davis TA; Stupp R; Sampson JH;
    Lancet Oncol; 2017 Oct; 18(10):1373-1385. PubMed ID: 28844499
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rindopepimut: a promising immunotherapeutic for the treatment of glioblastoma multiforme.
    Swartz AM; Li QJ; Sampson JH
    Immunotherapy; 2014; 6(6):679-90. PubMed ID: 25186601
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rindopepimut with Bevacizumab for Patients with Relapsed EGFRvIII-Expressing Glioblastoma (ReACT): Results of a Double-Blind Randomized Phase II Trial.
    Reardon DA; Desjardins A; Vredenburgh JJ; O'Rourke DM; Tran DD; Fink KL; Nabors LB; Li G; Bota DA; Lukas RV; Ashby LS; Duic JP; Mrugala MM; Cruickshank S; Vitale L; He Y; Green JA; Yellin MJ; Turner CD; Keler T; Davis TA; Sampson JH;
    Clin Cancer Res; 2020 Apr; 26(7):1586-1594. PubMed ID: 32034072
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The evolution of the EGFRvIII (rindopepimut) immunotherapy for glioblastoma multiforme patients.
    Paff M; Alexandru-Abrams D; Hsu FP; Bota DA
    Hum Vaccin Immunother; 2014; 10(11):3322-31. PubMed ID: 25625931
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The EGFR variant III mutant as a target for immunotherapy of glioblastoma multiforme.
    Chistiakov DA; Chekhonin IV; Chekhonin VP
    Eur J Pharmacol; 2017 Sep; 810():70-82. PubMed ID: 28583430
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting EGF receptor variant III: tumor-specific peptide vaccination for malignant gliomas.
    Del Vecchio CA; Li G; Wong AJ
    Expert Rev Vaccines; 2012 Feb; 11(2):133-44. PubMed ID: 22309662
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rindopepimut: an evidence-based review of its therapeutic potential in the treatment of EGFRvIII-positive glioblastoma.
    Babu R; Adamson DC
    Core Evid; 2012; 7():93-103. PubMed ID: 23055947
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The epidermal growth factor variant III peptide vaccine for treatment of malignant gliomas.
    Li G; Mitra S; Wong AJ
    Neurosurg Clin N Am; 2010 Jan; 21(1):87-93. PubMed ID: 19944969
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ReACT Phase II trial: a critical evaluation of the use of rindopepimut plus bevacizumab to treat EGFRvIII-positive recurrent glioblastoma.
    Gatson NT; Weathers SP; de Groot JF
    CNS Oncol; 2016; 5(1):11-26. PubMed ID: 26670466
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Detection of humoral response in patients with glioblastoma receiving EGFRvIII-KLH vaccines.
    Schmittling RJ; Archer GE; Mitchell DA; Heimberger A; Pegram C; Herndon JE; Friedman HS; Bigner DD; Sampson JH
    J Immunol Methods; 2008 Nov; 339(1):74-81. PubMed ID: 18775433
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The PEPvIII-KLH (CDX-110) vaccine in glioblastoma multiforme patients.
    Heimberger AB; Sampson JH
    Expert Opin Biol Ther; 2009 Aug; 9(8):1087-98. PubMed ID: 19591631
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Emerging immunotherapies for glioblastoma.
    Desai R; Suryadevara CM; Batich KA; Farber SH; Sanchez-Perez L; Sampson JH
    Expert Opin Emerg Drugs; 2016 Jun; 21(2):133-45. PubMed ID: 27223671
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting EGFRvIII for glioblastoma multiforme.
    Yang J; Yan J; Liu B
    Cancer Lett; 2017 Sep; 403():224-230. PubMed ID: 28649003
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Personalized neoantigen vaccines: a glimmer of hope for glioblastoma.
    Londhe VY; Date V
    Expert Rev Vaccines; 2020 May; 19(5):407-417. PubMed ID: 32238056
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rindopepimut: anti-EGFRvIII peptide vaccine, oncolytic.
    Gedeon PC; Choi BD; Sampson JH; Bigner DD
    Drugs Future; 2013 Mar; 38(3):147-155. PubMed ID: 25663738
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aptamer targeting EGFRvIII mutant hampers its constitutive autophosphorylation and affects migration, invasion and proliferation of glioblastoma cells.
    Camorani S; Crescenzi E; Colecchia D; Carpentieri A; Amoresano A; Fedele M; Chiariello M; Cerchia L
    Oncotarget; 2015 Nov; 6(35):37570-87. PubMed ID: 26461476
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glioblastoma Immunotherapy: A Systematic Review of the Present Strategies and Prospects for Advancements.
    Agosti E; Zeppieri M; De Maria L; Tedeschi C; Fontanella MM; Panciani PP; Ius T
    Int J Mol Sci; 2023 Oct; 24(20):. PubMed ID: 37894718
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.